Ivabradine–Flecainide as Breakthrough Drug Combination for Congenital Junctional Ectopic Tachycardia: A Case Report and Literature Review

Pediatric Reports

Angela Pepe¹  Annamaria Pagano²  Angelica De Nigris³  Giovanni Maria Di Marco⁴  Giangiacomo Di Nardo⁴  Vincenzo Tipo⁵ 

[1] Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, Pediatrics Section, University of Salerno, 84081 Baronissi, Italy;Department of Translational Medical Science, Pediatrics Section, University of Naples “Federico II”, 80126 Naples, Italy;Department of Woman, Child and General and Specialist Surgery, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy;Division of Cardiology, Department of Pediatrics, Santobono- Pausilipon Children Medical Hospital, 80129 Naples, Italy;Pediatric Emergency and Short Stay Unit, Santobono-Pausilipon Children’s Hospital, 80129 Naples, Italy;

关键词: ivabradine;    tachycardia;    junctional;    pediatrics;    congenital;   

DOI  :  10.3390/pediatric13040074

来源: DOAJ

【 摘 要 】

Congenital junctional ectopic tachycardia (CJET) is a rare tachyarrhythmia that remains difficult to manage, with suboptimal control in most cases. Here, we report literature research on the use of ivabradine in the treatment of pediatric junctional ectopic tachycardia (JET), both congenital and postoperative, and describe the successful use of ivabradine–flecainide association for CJET therapy resistant to other antiarrhythmic agents. This new drug combination was effective in completely suppressing JET. Ivabradine–flecainide combination may be considered a new therapeutic strategy of CJET with a satisfactory efficacy/tolerability ratio in patients resistant to conventional drug combinations.

【 授权许可】

Unknown